undamentalytics Newsletter
Sign in

Nektar Therapeutics cash flow statement

In fiscal 2025, Nektar Therapeutics's operations generated −$209m of cash; it spent $171,000 on capital projects, leaving free cash flow of −$209m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations40−56−114−130−39−142−73−117−80718−329−313−413−304−193−176−209−234
Depreciation and amortisation1517151514131113139111313127411
Stock-based pay1017191618172026378810094955733221312
Capital spending1631101141011610142671561100
Free cash flow23−87−123−140−43−152−84−123−90704−355−321−428−310−193−177−209−234
Free cash flow after stock pay13−105−142−157−60−169−104−149−127616−455−415−522−367−227−199−221−246
Share buybacks——————————————030—
Shares issued59220———————————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NKTR vs TNGXNKTR vs SIGAGOSS vs NKTRIVVD vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nektar Therapeutics's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nektar Therapeutics.